Effects of statin treatment with atorvastatin on urolithiasis-associated urinary metabolic risk factors: an experimental study
- 93 Downloads
To investigate whether atorvastatin has favorable effects on urinary metabolic risk factors associated with urolithiasis.
Sixteen male Sprague–Dawley rats were randomly divided into two groups, and baseline spot and 24-h urine samples were collected. Distilled water and atorvastatin were administered to rats during 4 weeks in the control and atorvastatin groups, respectively. At the end of the experimental procedure, spot and 24-h urine samples were collected again. Citrate, oxalate, cystine, uric acid, calcium and magnesium levels were determined in 24-h urine samples. Citrate/creatinine, oxalate/creatinine, uric acid/creatinine, calcium/creatinine and magnesium/creatinine ratios were also calculated in spot urine samples. Comparison of the baseline and post-experimental levels of these parameters was made in each group.
The majority of the parameters were similar before and after the experimental procedure in each group. In the atorvastatin group, uric acid and calcium levels were affected. Administration of atorvastatin was significantly decreased the levels of uric acid, whereas increased the levels of calcium (P = 0.025 and P = 0.017, respectively).
Our study revealed that atorvastatin has decreasing effect on UUa levels, whereas increasing effect on UCa levels. We think it cannot certainly be deduced that atorvastatin could be beneficial on overall urinary metabolic risk factors. Contrarily, atorvastatin may lead to an increased risk of calcium stones, but when considering its UUa decreasing effect, it may help in reducing the uric acid stone recurrence.
KeywordsStatins Atorvastatin Urolithiasis Urine Risk factors
We want to thank staffs of Experimental Animals Laboratory of Bagcilar Training and Research Hospital for their valuable supports during the experimental procedures.
Compliance with ethical standards
Conflict of interest
All authors declare to have no conflict of interest.
- 14.Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JL, Seman LJ, Ferrari A, Rubenstein JJ (2004) Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol 93:31–39CrossRefPubMedGoogle Scholar
- 16.Deutsche Bank Markets Research (2012) Industry European pharmaceuticals. Pharm Begin. https://workspace.imperial.ac.uk/ref/Public/UoA%2011%20-%20Computer%20Science%20and%20Informatics/4IXICO/A%20Market%20Research%20Deutsche%20Bank.pdf. Accessed 21 Oct 2017